NextFin news, On Thursday, October 2, 2025, US President Donald Trump announced sweeping new tariffs on pharmaceutical imports, including a 100% duty on branded or patented medicines entering the United States. The tariffs took effect on October 1, 2025, unless the importing company is actively constructing a manufacturing facility within the US.
The announcement, made on September 25, 2025, also included tariffs of 50% on kitchen cabinets, 30% on upholstered furniture, and 25% on heavy trucks. These measures follow investigations by the US Department of Commerce under Section 232 of the Trade Expansion Act of 1962, which allows tariffs on national security grounds.
The 100% tariff effectively doubles the cost of imported branded pharmaceuticals for US importers and consumers. The policy primarily targets multinational firms producing patented medicines in countries such as Switzerland, Britain, Singapore, China, and India. However, exemptions apply if a company is building or has begun construction of a US manufacturing plant.
Large pharmaceutical companies like Roche, Novartis, AstraZeneca, Johnson & Johnson, Merck, and Eli Lilly are expected to avoid the harshest penalties due to their existing or planned US production facilities. Generic drugs, which constitute the majority of US prescriptions, are not directly affected by the tariffs, though some branded generics may face uncertainty.
Indian pharmaceutical exporters, who shipped $3.7 billion worth of pharmaceuticals to the US in the first half of 2025, face significant challenges from the new tariffs. Companies such as Dr. Reddy’s, Sun Pharma, Lupin, and Aurobindo, which rely heavily on the US market, may be impacted, especially if their products fall under the branded or specialty medicine categories.
The tariffs pose a greater risk to smaller drugmakers lacking the resources of multinational giants, potentially forcing them to raise prices, reduce supply, or exit the US market. This could lead to shortages of specialized therapies and increased costs for patients.
In response to the tariffs, Indian pharmaceutical companies are urged to diversify export markets and invest in domestic reforms to enhance competitiveness. China has already reduced its import duty on generics to zero, signaling a strategic shift that may affect global pharmaceutical trade dynamics.
The Trump administration’s tariff strategy aligns with its broader agenda to reshore manufacturing and reduce the US trade deficit. Further sectoral tariffs, including on semiconductors, are reportedly under consideration.
Separately, Pfizer secured a three-year reprieve from these tariffs by agreeing to cut some drug prices by up to 85% and sell directly to the American public, addressing concerns over high US drug costs. Other major drugmakers are expected to follow suit.
The new tariffs have caused immediate market reactions, with Indian pharma stocks declining sharply following the announcement. The policy’s full impact remains to be seen as companies and governments navigate the evolving trade landscape.
Explore more exclusive insights at nextfin.ai.
